New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
12:34 EDTREGN, TWTR, STAA, FOLD, NFLX, SNY, AYIOn The Fly: Midday Wrap
Stocks on Wall Street were sharply higher at midday in the first trading day of the month and the new quarter. The market has not had such a good start to the second half of a year since 2011. The day’s domestic economic data was generally in-line with expectations, while reports from abroad confirmed that manufacturing expanded last month in China and in the eurozone. ECONOMIC EVENTS: In the U.S., two separate manufacturing readings were released. Markit's manufacturing purchasing manager's index for June had a final reading of 57.3, which was a hair below the 57.5 flash estimate but up from May's 56.4 reading. ISM's manufacturing index slipped very slightly to 55.3 in June from May's 55.4 figure. Construction spending increased 0.1% in May, missing the forecast for 0.5% growth. In China, the purchasing manager's index reading from HSBC and Markit came in at 50.7, which was a bit below the preliminary reading but above the 50 mark that indicates expansion for the first time since December. In Europe, Markit's final eurozone manufacturing PMI for June came in at 51.8, which was down from 52.2 in the prior month and below the earlier flash estimate of 51.9, but still indicated expansion in the sector. COMPANY NEWS: Shares of Netflix (NFLX) climbed 6% after Goldman Sachs upgraded the stock in a note to investors earlier today, predicting that Netflix's total worldwide market will more than double over the next three years and its subscriber growth will continue to exceed expectations... Twitter (TWTR) rose more than 4% after hiring Anthony Noto as its new Chief Financial Officer away from Goldman Sachs (GS), which had handled the social network's IPO. Noto served as a Managing Director in the Technology, Media and Telecom group at Goldman since October 2010 after having served as the CFO of the National Football League previously. MAJOR MOVERS: Among the notable gainers was Amicus Therapeutics (FOLD), which rose 23% following upgrades at Leerink and Janney Capital that came a day after the company provided updates on its potential monotherapy for Fabry patients. Also higher was Regeneron (REGN), which advanced 7% after Sanofi (SNY) disclosed in a regulatory filing that it plans to increase its beneficial ownership stake in its smaller pharmaceutical industry peer to 22.5% from 20.5%. Among the noteworthy losers was STAAR Surgical (STAA), which dropped 18% after it received a warning letter from the FDA following the regulator's inspection of a manufacturing plant. Also lower following its earnings reports was lighting solutions maker Acuity Brands (AYI), which fell 13% after its sales and profits missed expectations. INDEXES: Near midday, the Dow was up 134.80, or 0.8%, to 16,961.40, the Nasdaq was up 50.88, or 1.15%, to 4,459.06, and the S&P 500 was up 13.62, or 0.69%, to 1,973.85.
News For NFLX;TWTR;AYI;FOLD;REGN;SNY;STAA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
July 24, 2015
07:16 EDTSNY, REGNFDA PDUFA Date for Regeneron and Sanofi BLA for Praluent is July 24, 2015
Subscribe for More Information
05:53 EDTTWTRStocks with implied volatility above IV index mean; AMZN TWTR
Subscribe for More Information
July 23, 2015
20:01 EDTTWTRTwitter announces event targeting
Twitter announced, on its blog, that the company is instituting event-based advertisement targeting. The company stated that event targeting utilizes three tools, an event calendar, event insights, and event activation. The company stated, "With event targeting, you can activate around live moments, quickly and easily. We’ll help you discover and plan for these moments, learn more about the participating audiences through valuable insights, and with one click, create a campaign that delivers the right message to just the right users as the event unfolds." Event targeting is now available to all Twitter advertisers globally. Reference Link
13:53 EDTNFLX“Fab Five” option implied volatility
Subscribe for More Information
07:50 EDTTWTRBrean Capital cuts Twitter target to $47 on near-term risks
Subscribe for More Information
06:51 EDTNFLXDreamWorks upgraded to Market Perform from Underperform at FBR Capital
FBR Capital analyst Barton Crockett upgraded DreamWorks (DWA) to Market Perform saying growth from licensing more TV shows to Netflix (NFLX) should offset increased competition in core feature films. Crockett raised his price target for shares to $26.
July 22, 2015
15:02 EDTNFLXOptions Update; July 22, 2015
Subscribe for More Information
10:15 EDTNFLXOptions with decreasing implied volatility
Subscribe for More Information
10:01 EDTREGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:39 EDTREGNRegeneron initiated with a Market Perform at Northland
Northland analyst James Kuo started shares of Regeneron Pharmaceuticals with a Market Perform rating and $500 price target. Pointing out that shares are up 34% year-to-date and 80% year-over-year, Kuo prefers to watch the upcoming launch of Praluent from the sidelines.
07:41 EDTTWTRTwitter blocked by Turkey following recent terror attack, AP reports
Subscribe for More Information
06:12 EDTTWTRHerbalife requests user information from Twitter, Reuters reports
Herbalife (HLF) has filed a petition seeking information from Twitter (TWTR) to find an anonymous user who posted defamatory tweets against Herbalife, Reuters reports. Herbalife wants Twitter to provide IP addresses as well as account details of the user so that the company can pursue legal action, the report says. Reference Link
July 21, 2015
12:47 EDTSNY, REGNPiper confident in Regeneron approval by Friday
After Amgen's (AMGN) Repatha received marketing authorization in Europe, making it the first of the anti-PCSK9 antibody to be approved worldwide, Piper Jaffray analyst Edward Tenthoff expressed confidence that Regeneron (REGN) and Sanofi's (SNY) anti-PCSK9 antibody Praluent will be approved by Friday's FDA action date. Tenthoff believes Praluent will eventually be a blockbuster drug, but anticipates the launch to be slow. He keeps a Neutral rating on Regeneron with a $484 price target.
10:24 EDTNFLXOptions with decreasing implied volatility
Subscribe for More Information
09:35 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL FB IBM TSLA BAC PVA NFLX
July 20, 2015
16:01 EDTNFLXOptions Update; July 20, 2015
Subscribe for More Information
10:13 EDTNFLXOptions with decreasing implied volatility
Subscribe for More Information
09:53 EDTNFLXNetflix falls to session lows, levels to watch
Subscribe for More Information
09:34 EDTNFLXActive equity options trading on open
Subscribe for More Information
06:06 EDTTWTRStocks with implied volatility above IV index mean; XOMA TWTR
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use